CompletedPhase 3

Treatment of Moderate to Severe Lateral Canthal Lines

United States303 participantsStarted 2020-02-10

Plain-language summary

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female 18 years of age or older.
✓. Moderate to severe LCL at maximum smile as assessed by the Investigator.
✓. Moderate to severe LCL at maximum smile as assessed by the subject.

Exclusion criteria

✕. Previous use of any Botulinum toxin treatment in facial areas within 9 months prior to study treatment.
✕. Female who is pregnant, breast feeding, or intends to conceive a child during the study.
✕. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.

What they're measuring

Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Line Investigator and Subject Assessments at Maximum Smile at One Month.

Timeframe: Month 1

Trial details

NCT IDNCT04249687

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-09-25

Results submitted2023-05-23

View on ClinicalTrials.gov More Lateral Canthal Lines trials